| Douglas Eugene Carlson, DO | |
|
4504 Ridge Rd, Alma, AR 72921-7488 | |
| (479) 430-0626 | |
| Not Available |
| Full Name | Douglas Eugene Carlson |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 4504 Ridge Rd, Alma, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396707808 | NPI | - | NPPES |
| 155935003 | Medicaid | AR | |
| 200041730A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | E4230 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johnson Regional Medical Center | Clarksville, AR | Hospital |
| Mccurtain Memorial Hospital | Idabel, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| East Arkansas Emergency Physicians Pllc | 5698909067 | 22 |
| Mccurtain Memorial Medical Management, Inc. | 8022926252 | 17 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility.
Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.
From low-income countries to high-income countries, long-term exposure to fine particulate outdoor air pollution is a major contributor to cardiovascular disease and death, a new Oregon State University study found.
› Verified 7 days ago
| Entity Name | Southeastern Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356379382 PECOS PAC ID: 2466364997 Enrollment ID: O20050418001201 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility.
Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.
From low-income countries to high-income countries, long-term exposure to fine particulate outdoor air pollution is a major contributor to cardiovascular disease and death, a new Oregon State University study found.
› Verified 7 days ago
| Entity Name | East Arkansas Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932442985 PECOS PAC ID: 5698909067 Enrollment ID: O20131018000502 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility.
Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.
From low-income countries to high-income countries, long-term exposure to fine particulate outdoor air pollution is a major contributor to cardiovascular disease and death, a new Oregon State University study found.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Eugene Carlson, DO 4504 Ridge Rd, Alma, AR 72921-7488 Ph: (479) 430-0626 | Douglas Eugene Carlson, DO 4504 Ridge Rd, Alma, AR 72921-7488 Ph: (479) 430-0626 |
News Archive
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility.
Colorectal cancer is the second leading cause of cancer death in the U.S., expected to cause about 51,000 deaths in 2019. But until now, it was unclear which drugs were most effective for which patients.
From low-income countries to high-income countries, long-term exposure to fine particulate outdoor air pollution is a major contributor to cardiovascular disease and death, a new Oregon State University study found.
› Verified 7 days ago